Ilya V. Tsimafeyeu

Abstract B036: Prevalence of non-clear cell renal cell carcinoma based on new WHO classification: Results from a multicenter BUCARE Study

Vladislav Vladimirovich Petkau, Dmitrii Iu. Shemetov, Sufia Safina, Olga Novikova et autres

Abstract Background: The reported prevalence of non-clear cell renal cell carcinoma (nccRCC) has varied across studies for years, partially due to evolving WHO classifications and improvements in pathological diagnosis. These changes may have impacted the true prevalence of nccRCC in daily practice. …

ru (code pays fourni par la source)

A randomized phase 2 trial of lenvatinib plus pembrolizumab with or without stereotactic body radiotherapy in patients with metastatic renal cell carcinoma, low tumor burden, and stable disease (LASER).

Ilya V. Tsimafeyeu, A. A. Lebedinets, Makhabbat Zh. Murzalina, A. A. Zhuravlev et autres

TPS583 Background: Lenvatinib plus pembrolizumab (Len+P) is an established first-line regimen for metastatic clear cell renal cell carcinoma (mRCC). In the CLEAR study, patients with low tumor burden derived substantial benefit; however, ~20% achieved only stable disease (SD) as best response. In …

us, ru (code pays fourni par la source)

Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma and venous tumor thrombus: Results from the first analysis of the PELET trial.

Mark Gluzman, Svetlana Averianova, Д. М. Дубовиченко, Olesya A. Goncharova et autres

509 Background: Venous tumor thrombus (VTT) in patients with renal cell carcinoma (RCC) represents an aggressive disease feature associated with poor prognosis and management challenges. The efficacy of immunotherapy-based combinations in this subgroup remains insufficiently characterized. Methods: The PELET trial is an …

ru, us (code pays fourni par la source)

Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma

Ilya V. Tsimafeyeu, Fuad Guliyev, Bakytzhan Ongarbayev, Г А Мусаева et autres

us, az, kz, ru (code pays fourni par la source)

Preclinical rationale for FGFR1 blockade in colorectal cancer.

Dmitry A. Khochenkov, Yulia A. Khochenkova, Yulia Baula, Qingqing Wang et autres

164 Background: Aberrant activation of fibroblast growth factor receptor (FGFR) pathways contributes to tumor progression in colorectal cancer (CRC), often through ligand-mediated stimulation of extracellular domains. To address this, we evaluated the preclinical activity of OM-RCA-01, a humanized monoclonal antibody selectively targeting …

us (code pays fourni par la source)

Abstract A138: Extracellular FGFR1 inhibition with OM-RCA-01 humanized antibody suppresses tumor growth in FGFR1-expressing colorectal cancer models

Yulia Khochenkova, Dmitry A. Khochenkov, Yuliya Baula, Qingqing Wang et autres

Abstract Background: Fibroblast growth factor receptor (FGFR) signaling in colorectal cancer (CRC) can be driven by ligand-dependent activation of its extracellular domains. We hypothesized that selective targeting of the extracellular II–IIIc domains using OM-RCA-01 - a humanized monoclonal antibody against FGFR1 - …

ru, us (code pays fourni par la source)

2158P Efficacy and safety of second-line ramucirumab plus paclitaxel in FGFR2 and PD-L1 co-expressing metastatic gastric cancer refractory to first-line nivolumab and chemotherapy: Results from the phase II NIVOFGFR2 study

Gunel Musayeva, Ilya V. Tsimafeyeu, S. Makhmudova

az, us (code pays fourni par la source)

Maintenance avelumab in metastatic urothelial carcinoma: do tumour site and previous surgery matter?

Ruslan A. Zukov, Yana Gridneva, Yulia Anzhiganova, А. В. Султанбаев et autres

ru, us (code pays fourni par la source)

Efficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial

Viacheslav A Chubenko, O. V. Baklanova, Alexey S. Kalpinskiy, Sufia Safina et autres

Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus …

ru, us (code pays fourni par la source)

Real-world outcomes of lenvatinib plus pembrolizumab in intermediateand poor-risk metastatic renal cell carcinoma

Ilya V. Tsimafeyeu, А. В. Султанбаев, Д. М. Дубовиченко, Makhabbat Zh. Murzalina et autres

Background. The combination of lenvatinib and pembrolizumab demonstrated significant efficacy in the phase 3 CLEAR study for metastatic renal cell carcinoma (RCC). However, poor-risk patients represented only a small proportion of the trial population.Aim. This multicenter retrospective cohort study assessed the real-world …

us, ru, il (code pays fourni par la source)

Prevalence of erectile dysfunction and its association with age in patients with metastatic renal cell carcinoma: results from a prospective multicenter study

Yulia Tishova, Ruslan A. Zukov, Лев Вадимович Демидов, Pavel S. Borisov et autres

BACKGROUND: This study aimed to evaluate the prevalence of erectile dysfunction (ED) and assess its associations in a large cohort of patients with metastatic renal cell carcinoma (mRCC) prior to initiating and during therapy. METHODS: In this prospective multicenter study, male patients …

ru, us (code pays fourni par la source)

Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy

Ilya V. Tsimafeyeu

Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in the progression of various cancers through its involvement in cell proliferation, survival, and differentiation. More recently, FGFR1 has been implicated in the mechanisms of immune evasion, particularly its role in resistance …

us (code pays fourni par la source)